Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Osaka, OsakaFounded 2021110 employeesWebsite
A generic pharmaceutical group centered on Sawai Pharmaceutical. It has one of Japan's broadest generic product portfolios and focuses on reliable supply and affordable healthcare.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Pharmaceutical Manufacturing and Sales | 100% | ¥201.7B | ¥15.9B | 7.9% |
Close (Oct 30, 2026)
¥1,666.5-9.2% (1Y)
Sawai -9.2% over 1Y, 22.8pt below the industry average (23 companies, +13.6%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥201.7B | ¥15.9B | ¥10.4B | ¥359.9B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
